Aquestive Therapeutics enters the final week of June carrying two contradictory signals: the stock is up 7.6% over the past month — riding a 43.77% spike after the FDA waived an advisory committee meeting for its Anaphylm NDA — yet insiders have been steady sellers throughout the rally, and the ORTEX short score remains elevated near 78.
The insider selling is the most notable thread this week. CEO Daniel Barber sold $1.4 million worth of shares on May 5, followed by a further $104,000 on June 15. The Chief Legal Officer sold $574,000 on May 7, the COO sold $304,000 on May 5, and the CFO trimmed $387,000 the same day. Most recently, director Julie Krop sold 25,000 shares on June 23. In aggregate, net insider sales over the past 90 days total roughly $3.5 million across more than 832,000 net shares. None of these trades are enormous relative to the company's total float, and several appear routine in size and cadence — but the breadth is worth noting. At least six different insiders sold into the rally rather than adding, suggesting the executive team views the post-FDA pop as an exit window rather than a precursor to further upside.
Short positioning paints a complicated picture alongside that insider activity. Short interest is genuinely elevated — roughly 11.9% of the free float, though it has declined about 7.3% over the past month as some shorts have covered. Borrow availability has loosened slightly this week to around 28%, up from a tighter 14-16% range seen in mid-June. Cost to borrow is modest at 1.24%, up about 22% over a month but nowhere near the territory that would signal a borrow squeeze. The ORTEX short score of 77.8 places AQST in the 4th percentile on short score rank — meaning nearly all comparable names carry a lower short-risk signal — but the score has actually drifted down from 79 a week ago as some shorts exit. The days-to-cover figure from official FINRA data sits at 9.5, meaning it would take nearly two weeks of average volume to clear the short book, a meaningful overhang for a small-cap name. Options positioning flips the story sharply: the put/call ratio has collapsed to 0.27, nearly 1.6 standard deviations below its 20-day average of 0.46. Call volume is heavily dominant, suggesting the options market is far more bullish than the short book implies. That divergence — heavy call buying against an elevated short base and insider selling — is the central tension in AQST right now.
The Street's collective view remains constructive but dated. The most recent analyst changes on record are from late 2025, with Piper Sandler raising its target to $8 in November and JMP Securities lifting to $12 in October. HC Wainwright has repeatedly reiterated Buy at $10. The consensus mean target of $8.89 implies roughly 100% upside to the current $4.39 price — though that gap reflects both genuine Street optimism about Anaphylm and the staleness of the data, with the analyst record last updated in early March 2026. Bulls point to Aquestive's positioning in the no-needle epinephrine market and the FDA's decision to skip an advisory committee as concrete de-risking of the NDA pathway. Bears flag pipeline execution risk on AQST-109, potential revenue erosion from licensed commercial products, and balance sheet concerns that could necessitate a capital raise. The forward EPS improvement estimate ranks in the 94th percentile on a 12-month basis — an extraordinary number — but the company currently earns nothing, with deeply negative ROA and FCF/sales ratios that keep quality scores in the low 20s.
Among correlated peers, the week has been mixed. PCRX climbed 13% on the week while CRMD fell 9.5% and OMER dropped 15.7%, suggesting no clear directional tide in specialty pharma. AQST's own 6.8% weekly decline tracks closer to the losing side of that peer spread, despite the still-intact post-FDA narrative.
The next earnings event is scheduled for August 7. With an NDA review outcome potentially arriving before then, the question worth tracking is whether the options-driven call enthusiasm is front-running a regulatory decision — or simply a lingering artifact of last week's FDA catalyst — and whether insiders continue to reduce exposure as the date approaches.
See the live data behind this article on ORTEX.
Open AQST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
